Sufficiency in the English courts - the Regeneron story (part 2)

As a follow-on from last week's Regeneron v Kymab webinar, where we looked at how and why the Supreme Court reversed the Court of Appeal and found Regeneron's patents for transgenic mouse technology invalid for insufficiency, we pick up the discussion to reflect on the broader impact of the ruling.